London Calling 2025 - Speakers
Speakers
Check out the line up of speakers at London Calling 2025.
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
Oxford Nanopore Technologies
Benjamin C. Reiner
)
- Job title
- Institution
- University of Pennsylvania, USA
- Biography
Benjamin Reiner earned a PhD in Pharmacology and Experimental Neuroscience from the University of Nebraska Medical Center and completed his Postdoctoral Fellowship in the Department of Psychiatry at the University of Pennsylvania Perelman School of Medicine. Now a Research Assistant Professor in the same department, his laboratory focuses on using behavioral, pharmacological, and intersectional genetic approaches with neural multiomics and downstream bioinformatics in preclinical animal models of psychiatric disease, substance use disorders, and diseases of feeding and energy balance.
- Recent publications
Khatri S.N. et al. Xylazine suppresses fentanyl consumption during self-administration and induces a unique sex-specific withdrawal syndrome that is not altered by naloxone in rats. Exp Clin Psychopharmacol. 32(2):150–157 (2024). DOI: 10.1037/pha0000670
Sadek S.M. et al. Impacts of xylazine on fentanyl demand, body weight, and acute withdrawal in rats: A comparison to lofexidine. Neuropharmacology 245:109816 (2024).
DOI: 10.1016/j.neuropharm.2023.109816
Talks at this conference
Oxford Nanopore Technologies products are RUO. Products labelled/branded as Oxford Nanopore Diagnostics may be RUO or may be regulated as in-vitro diagnostic devices in some jurisdictions, please check individual product labelling. Oxford Nanopore Technologies present the materials of third parties within the user community acknowledging that those materials belong to and are the true statements and representations of those third parties. Oxford Nanopore Technologies make no endorsements of the materials shown and the statements made.